Researchers identify the TRPV4 ion channel as the body's internal "stop scratching" signal, offering new hope for chronic itch relief.

Outside of winter, chronic itch affects millions of people with conditions including eczema, psoriasis, and kidney disease. Understanding the precise biological mechanisms that regulate itch—including ...

When you scratch an itch, something tells your brain when to stop. That moment of relief, when scratching feels "enough," is not accidental. Scientists have now identified a key molecular and neural ...

Denorex Severe Itch targets intense, recurring scalp itch at the source - responding to a common but often overlooked ...

Why aren't we talking about it more?

FAT jabs may help thousands of Brits beat a debilitating skin condition as well as shed the pounds, research suggests.

New findings indicate that in adults with moderate-to-severe plaque psoriasis who are overweight or obese, combined treatment with ixekizumab (Taltz) and tirzepatide (Zepbound) results ...

Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with ...

At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance ...

Eli Lilly said on Wednesday the combined use of its weight-loss drug Zepbound with psoriasis treatment Taltz showed better results in a late-stage ​study.

In this video interview, Linda Stein Gold, MD, director of dermatology clinical research and division head of dermatology at Henry Ford Health System, discussed her presentation on new treatments for ...